HK1186736A1 - (e)-n-(2-amino-phenyl)-3-1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]- 1h-pyrrol-3-yl-acrylamide tosylate salt (e)-n-(2--)-3-1-[4-(1--1h--4-)-]-1h--3-- - Google Patents
(e)-n-(2-amino-phenyl)-3-1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]- 1h-pyrrol-3-yl-acrylamide tosylate salt (e)-n-(2--)-3-1-[4-(1--1h--4-)-]-1h--3--Info
- Publication number
- HK1186736A1 HK1186736A1 HK13114246.8A HK13114246A HK1186736A1 HK 1186736 A1 HK1186736 A1 HK 1186736A1 HK 13114246 A HK13114246 A HK 13114246A HK 1186736 A1 HK1186736 A1 HK 1186736A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benzenesulfonyl
- pyrrol
- pyrazol
- phenyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08004568A EP2100882A1 (fr) | 2008-03-12 | 2008-03-12 | Sels d'acrylamide (E) -N -(2-Amino-phényl) -3-{1-[4-(1-méthyl-1H-pyrazol-4-yl)-benzènesulfonyl] -1H-pyrrol-3-yl} |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1186736A1 true HK1186736A1 (en) | 2014-04-17 |
Family
ID=39322749
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13114246.8A HK1186736A1 (en) | 2008-03-12 | 2013-12-24 | (e)-n-(2-amino-phenyl)-3-1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]- 1h-pyrrol-3-yl-acrylamide tosylate salt (e)-n-(2--)-3-1-[4-(1--1h--4-)-]-1h--3-- |
HK15108828.4A HK1208219A1 (en) | 2008-03-12 | 2015-09-10 | (e)-n-(2-amino-phenyl)-3-1-[4-(1-methyl-1h-pyrazol-4-yl)- benzenesulfonyl]-1h-pyrrol-3-yl-acrylamide tosylate salt (e)-n-(2--)-3-1-[4-(1--1h--4-)-]-1h-- 3-- |
HK18115376.2A HK1256310A1 (zh) | 2008-03-12 | 2018-11-30 | N-磺酰基吡咯衍生物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108828.4A HK1208219A1 (en) | 2008-03-12 | 2015-09-10 | (e)-n-(2-amino-phenyl)-3-1-[4-(1-methyl-1h-pyrazol-4-yl)- benzenesulfonyl]-1h-pyrrol-3-yl-acrylamide tosylate salt (e)-n-(2--)-3-1-[4-(1--1h--4-)-]-1h-- 3-- |
HK18115376.2A HK1256310A1 (zh) | 2008-03-12 | 2018-11-30 | N-磺酰基吡咯衍生物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8557858B2 (fr) |
EP (2) | EP2100882A1 (fr) |
JP (2) | JP2011513466A (fr) |
KR (1) | KR101657718B1 (fr) |
CN (5) | CN103360371B (fr) |
AU (1) | AU2009224710B2 (fr) |
BR (1) | BRPI0908917A2 (fr) |
CA (1) | CA2719071C (fr) |
EA (1) | EA017533B1 (fr) |
HK (3) | HK1186736A1 (fr) |
IL (1) | IL207994A (fr) |
MX (1) | MX2010010014A (fr) |
NZ (1) | NZ587823A (fr) |
UA (1) | UA106351C2 (fr) |
WO (1) | WO2009112522A1 (fr) |
ZA (1) | ZA201006523B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52937B (en) * | 2004-03-11 | 2014-02-28 | 4Sc Ag | SULFONYLPYROLS AS HDAC INHIBITORS |
EP2330894B8 (fr) | 2008-09-03 | 2017-04-19 | BioMarin Pharmaceutical Inc. | Compositions comprenant des dérivés d acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac |
JP6250403B2 (ja) | 2011-02-28 | 2017-12-20 | バイオマリン ファーマシューティカル インク | ヒストン脱アセチル化酵素阻害剤 |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CN102526714B (zh) * | 2011-08-24 | 2013-12-25 | 贵州神奇集团控股有限公司 | 治疗肿瘤的药物组合物及其制备方法 |
CN102716465B (zh) * | 2012-06-18 | 2014-01-15 | 贵州金桥药业有限公司 | 治疗肿瘤的药物组合物及其制备方法 |
KR20150132345A (ko) | 2013-03-15 | 2015-11-25 | 바이오마린 파머수티컬 인크. | Hdac 저해제 |
WO2017060524A1 (fr) * | 2015-10-09 | 2017-04-13 | 4Sc Ag | (e)-n-(2-aminophényl)-3-(1-((4-(1-méthyl-1h-pyrazol-4-yl)phényl)sulfonyl)-1h-pyrrol-3-yl)acrylamide pour le traitement d'infections virales latentes |
JP2020533320A (ja) | 2017-09-08 | 2020-11-19 | 4エスツェー アクチェンゲゼルシャフト | 癌療法のための免疫チェックポイント調節薬と併用したhdac阻害薬 |
JP2021519292A (ja) | 2018-03-26 | 2021-08-10 | 4エスツェー アクチェンゲゼルシャフト | 癌療法のためのhdac阻害薬とcd137作動薬とを含む併用 |
TW202011959A (zh) | 2018-04-14 | 2020-04-01 | 美商戴納瓦克斯技術公司 | 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合 |
TW202012395A (zh) * | 2018-04-14 | 2020-04-01 | 德商4Sc製藥公司 | 用於治療癌症的包含組蛋白去乙醯酶(hdac)抑制劑和tlr7 激動劑和/或tlr8 激動劑的藥物組合產品 |
MX2020011002A (es) * | 2018-04-17 | 2021-01-29 | 4Sc Ag | Combinacion que comprende inhibidor de hdac, inhibidor de lag-3 y un inhibidor de pd-1 o inhibidor de pd-l1 para el tratamiento del cancer. |
TW202114659A (zh) | 2019-10-02 | 2021-04-16 | 德商4Sc製藥公司 | 用於癌症治療之含hdac抑制劑、ctla—4抑制劑及pd—1抑制劑或pd—l1抑制劑之組合 |
CN111973590A (zh) * | 2020-07-06 | 2020-11-24 | 江苏省人民医院(南京医科大学第一附属医院) | 新型hdac抑制剂laq824在治疗弥漫大b细胞淋巴瘤药物中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4960787A (en) | 1989-02-06 | 1990-10-02 | Ciba-Geigy Corporation | Certain pyrrolyl-substituted hydroxamic acid derivatives |
AU5886296A (en) | 1995-06-02 | 1996-12-18 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors |
KR20100035666A (ko) | 1999-11-23 | 2010-04-05 | 메틸진 인크. | 히스톤 디아세틸라제의 억제제 |
EP1425577A4 (fr) * | 2001-08-10 | 2004-12-29 | Symyx Technologies Inc | Appareils et procedes permettant d'elaborer et de tester des pre-formulations et systemes correspondants |
RS52937B (en) * | 2004-03-11 | 2014-02-28 | 4Sc Ag | SULFONYLPYROLS AS HDAC INHIBITORS |
DE602006007558D1 (de) * | 2005-03-15 | 2009-08-13 | 4Sc Ag | N-sulfonylpyrrole und ihre verwendung als histondeacetylaseinhibitoren |
WO2006105979A1 (fr) * | 2005-04-07 | 2006-10-12 | Nycomed Gmbh | Sulfonylpyrroles en tant qu'inhibiteurs d'histone deacetylase |
NZ566073A (en) * | 2005-09-21 | 2011-08-26 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
PL1928872T3 (pl) * | 2005-09-21 | 2012-08-31 | 4Sc Ag | Nowe sulfonylopirole jako inhibitory HDAC |
EP2100878A1 (fr) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | Nouveau procédé pour la production de sulphonylpyrroles en tant qu'inhibiteurs HDAC |
-
2008
- 2008-03-12 EP EP08004568A patent/EP2100882A1/fr not_active Ceased
-
2009
- 2009-03-11 EA EA201001269A patent/EA017533B1/ru not_active IP Right Cessation
- 2009-03-11 CN CN201310174309.8A patent/CN103360371B/zh active Active
- 2009-03-11 EP EP09720914.2A patent/EP2262775B1/fr active Active
- 2009-03-11 CN CN2009801088445A patent/CN101970411A/zh active Pending
- 2009-03-11 CN CN201910349052.2A patent/CN110183425A/zh active Pending
- 2009-03-11 US US12/921,889 patent/US8557858B2/en active Active
- 2009-03-11 AU AU2009224710A patent/AU2009224710B2/en active Active
- 2009-03-11 JP JP2010550190A patent/JP2011513466A/ja not_active Withdrawn
- 2009-03-11 BR BRPI0908917-9A patent/BRPI0908917A2/pt active Search and Examination
- 2009-03-11 CA CA2719071A patent/CA2719071C/fr active Active
- 2009-03-11 CN CN201711442629.1A patent/CN108101890A/zh active Pending
- 2009-03-11 CN CN201510020638.6A patent/CN104803988A/zh active Pending
- 2009-03-11 MX MX2010010014A patent/MX2010010014A/es active IP Right Grant
- 2009-03-11 NZ NZ587823A patent/NZ587823A/en unknown
- 2009-03-11 KR KR1020107022664A patent/KR101657718B1/ko active IP Right Grant
- 2009-03-11 WO PCT/EP2009/052859 patent/WO2009112522A1/fr active Application Filing
- 2009-11-03 UA UAA201011867A patent/UA106351C2/ru unknown
-
2010
- 2010-09-05 IL IL207994A patent/IL207994A/en active IP Right Grant
- 2010-09-10 ZA ZA2010/06523A patent/ZA201006523B/en unknown
-
2013
- 2013-12-24 HK HK13114246.8A patent/HK1186736A1/xx unknown
-
2014
- 2014-03-26 JP JP2014063486A patent/JP5952328B2/ja active Active
-
2015
- 2015-09-10 HK HK15108828.4A patent/HK1208219A1/xx unknown
-
2018
- 2018-11-30 HK HK18115376.2A patent/HK1256310A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NZ587823A (en) | 2012-05-25 |
EP2100882A1 (fr) | 2009-09-16 |
CA2719071A1 (fr) | 2009-09-17 |
JP2014132027A (ja) | 2014-07-17 |
EA017533B1 (ru) | 2013-01-30 |
EP2262775B1 (fr) | 2024-09-04 |
JP5952328B2 (ja) | 2016-07-13 |
CN108101890A (zh) | 2018-06-01 |
KR20100133422A (ko) | 2010-12-21 |
IL207994A0 (en) | 2010-12-30 |
MX2010010014A (es) | 2011-04-05 |
CN104803988A (zh) | 2015-07-29 |
HK1256310A1 (zh) | 2019-09-20 |
CA2719071C (fr) | 2016-07-12 |
JP2011513466A (ja) | 2011-04-28 |
ZA201006523B (en) | 2011-09-28 |
CN110183425A (zh) | 2019-08-30 |
HK1208219A1 (en) | 2016-02-26 |
EA201001269A1 (ru) | 2011-06-30 |
US8557858B2 (en) | 2013-10-15 |
CN103360371A (zh) | 2013-10-23 |
KR101657718B1 (ko) | 2016-09-19 |
UA106351C2 (en) | 2014-08-26 |
AU2009224710A1 (en) | 2009-09-17 |
US20110086897A1 (en) | 2011-04-14 |
CN101970411A (zh) | 2011-02-09 |
IL207994A (en) | 2015-10-29 |
EP2262775A1 (fr) | 2010-12-22 |
BRPI0908917A2 (pt) | 2021-04-13 |
CN103360371B (zh) | 2015-03-25 |
AU2009224710B2 (en) | 2013-05-02 |
WO2009112522A1 (fr) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208219A1 (en) | (e)-n-(2-amino-phenyl)-3-1-[4-(1-methyl-1h-pyrazol-4-yl)- benzenesulfonyl]-1h-pyrrol-3-yl-acrylamide tosylate salt (e)-n-(2--)-3-1-[4-(1--1h--4-)-]-1h-- 3-- | |
IL209980A0 (en) | Sulfonamide compounds or salts thereof | |
IL205742A0 (en) | 4-(4-cyano-2-thioaryl) | |
AU322949S (en) | Vibrator | |
GB0811643D0 (en) | New therapeutic agents | |
GB2476842B (en) | Forceps | |
GB0808711D0 (en) | Tissue assessment | |
BRPI0822849A2 (pt) | Aparelho para cirurgia oftalmológica | |
EP2349266A4 (fr) | Composés contenant du sulfamide et leurs utilisations | |
IL208519A0 (en) | Substituted sulfonamide derivatives | |
BRPI0909659A2 (pt) | tratamento para distúrbios relacionados oculares | |
ZA201006548B (en) | Pyrimidylmethyl sulfonamide compounds | |
AP2612A (en) | Improved herbicidal formulation | |
GB2446447B (en) | Tissue tensiometer | |
GB0821478D0 (en) | Novel skin brightening agents | |
GB0901480D0 (en) | Contrast agents | |
GB0821135D0 (en) | Lanthanide compounds | |
GB0820674D0 (en) | Benzamide compounds | |
ES1068841Y (es) | Armario para terminales de usuario | |
AU4585P (en) | WES05 Westringia fruticosa | |
GB0800265D0 (en) | Tissue monitor | |
ES1068189Y (es) | Cabezal para mochos de fregona | |
GB0722374D0 (en) | Benzamide compounds | |
GB0815765D0 (en) | New therapeutic agents | |
GB0813220D0 (en) | Dual aspect dissecting forceps |